Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

186 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A phase I clinical study of a live attenuated Bordetella pertussis vaccine--BPZE1; a single centre, double-blind, placebo-controlled, dose-escalating study of BPZE1 given intranasally to healthy adult male volunteers.
Thorstensson R, Trollfors B, Al-Tawil N, Jahnmatz M, Bergström J, Ljungman M, Törner A, Wehlin L, Van Broekhoven A, Bosman F, Debrie AS, Mielcarek N, Locht C. Thorstensson R, et al. Among authors: ljungman m. PLoS One. 2014 Jan 8;9(1):e83449. doi: 10.1371/journal.pone.0083449. eCollection 2014. PLoS One. 2014. PMID: 24421886 Free PMC article. Clinical Trial.
Safety and immunogenicity of the live attenuated intranasal pertussis vaccine BPZE1: a phase 1b, double-blind, randomised, placebo-controlled dose-escalation study.
Jahnmatz M, Richert L, Al-Tawil N, Storsaeter J, Colin C, Bauduin C, Thalen M, Solovay K, Rubin K, Mielcarek N, Thorstensson R, Locht C; BPZE1 study team. Jahnmatz M, et al. Lancet Infect Dis. 2020 Nov;20(11):1290-1301. doi: 10.1016/S1473-3099(20)30274-7. Epub 2020 Jul 17. Lancet Infect Dis. 2020. PMID: 32687804 Clinical Trial.
Surveillance of Circulating Bordetella pertussis Strains in Europe during 1998 to 2015.
Barkoff AM, Mertsola J, Pierard D, Dalby T, Hoegh SV, Guillot S, Stefanelli P, van Gent M, Berbers G, Vestrheim DF, Greve-Isdahl M, Wehlin L, Ljungman M, Fry NK, Markey K, Auranen K, He Q. Barkoff AM, et al. Among authors: ljungman m. J Clin Microbiol. 2018 Apr 25;56(5):e01998-17. doi: 10.1128/JCM.01998-17. Print 2018 May. J Clin Microbiol. 2018. PMID: 29491017 Free PMC article.
Pertactin-deficient Bordetella pertussis isolates: evidence of increased circulation in Europe, 1998 to 2015.
Barkoff AM, Mertsola J, Pierard D, Dalby T, Hoegh SV, Guillot S, Stefanelli P, van Gent M, Berbers G, Vestrheim D, Greve-Isdahl M, Wehlin L, Ljungman M, Fry NK, Markey K, He Q. Barkoff AM, et al. Among authors: ljungman m. Euro Surveill. 2019 Feb;24(7):1700832. doi: 10.2807/1560-7917.ES.2019.24.7.1700832. Euro Surveill. 2019. PMID: 30782265 Free PMC article.
Antibody responses to Bordetella pertussis Fim2 or Fim3 following immunization with a whole-cell, two-component, or five-component acellular pertussis vaccine and following pertussis disease in children in Sweden in 1997 and 2007.
Hallander H, Advani A, Alexander F, Gustafsson L, Ljungman M, Pratt C, Hall I, Gorringe AR. Hallander H, et al. Among authors: ljungman m. Clin Vaccine Immunol. 2014 Feb;21(2):165-73. doi: 10.1128/CVI.00641-13. Epub 2013 Dec 4. Clin Vaccine Immunol. 2014. PMID: 24307240 Free PMC article. Clinical Trial.
Two consecutive randomized controlled pertussis booster trials in children initially vaccinated in infancy with an acellular vaccine: The first with a five-component Tdap vaccine to 5-year olds and the second with five- or monocomponent Tdap vaccines at age 14-15 years.
Carlsson RM, Gustafsson L, Hallander HO, Ljungman M, Olin P, Gothefors L, Nilsson L, Netterlid E. Carlsson RM, et al. Among authors: ljungman m. Vaccine. 2015 Jul 17;33(31):3717-25. doi: 10.1016/j.vaccine.2015.05.079. Epub 2015 Jun 7. Vaccine. 2015. PMID: 26057135 Clinical Trial.
186 results